MRI-Guided Focused Ultrasound Feasibility Study for Brain Tumors
Brain Tumor
Conditions: official terms
Brain Neoplasms
Conditions: Keywords
Brain tumor, Brain Lesions, Brain Cancer, ExAblate
Study Type
Study Phase
Phase 1
Study Design
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Name: ExAblate transcranial system
Type: Device
Overall Status
The purpose of this study is to evaluate the safety of MRI-guided focused ultrasound thermal ablation of brain tumors performed through intact human skull using the ExAblate transcranial system. We will collect data to establish the basic safety of this type of treatment as the basis for later studies that will evaluate its clinical efficacy.
Detailed Description
In this non-randomized feasibility study, FUS under MRI-guidance and thermometry will be given through intact human skull to brain tumor in up to ten (10) subjects. These subjects will be followed over a 3-month period with contrast MRI and clinical exams.

The objectives are:

1. To evaluate the safety of ExAblate TcMRgFUS treatment delivered through intact human skull to the brain, during the treatment, and during the follow-up period of 3 months.

2. To evaluate the effect of thermal ablation in the target tumor with contrast MR imaging to identify viable tumor, and non-viable thermally ablated tissue.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 70 Years
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

1. Tumor(s) are clearly defined on pre-therapy contrast enhanced MRI scans.

2. Men or women.

3. Age between 18 and 70 years, inclusive.

4. Karnofsky rating 70-100.

5. ASA score 1-2.

6. Able and willing to give informed consent.

7. Able to communicate sensations during the ExAblate MRGFUS procedure.

8. Apparently able to attend all study visits (i.e., life expectancy of at least 3 months).

9. At least 14 days passed since last brain surgery, or intracranial radiation therapy/radiosurgery

10. No additional tumor brain surgery nor radiation therapy anticipated for at least 14 days.

Exclusion Criteria:

1. The subject presents with:

- Symptoms and signs of increased intracranial pressure (e.g., headache, nausea, vomiting, lethargy, and papaedema).

- Unstable hemodynamic status including: i. Documented myocardial infarction within six months of enrollment. ii.Symptomatic coronary artery stenosis. iii. Congestive heart disease requiring medication. iv. Anti-arrhythmic drug medication. v. Cardiac pacemaker. vi. Severe hypertension (diastolic BP > 100 on medication).

2. Anti-coagulant therapy, on medications known to increase risk of hemorrhage, (e.g.: non-steroidal anti-inflammatory drugs (NSAIDs), statins

3. TIA or stroke in the last 1 month

4. Insulin-dependent diabetes mellitus

5. Immunosuppression (corticosteroids to prevent brain edema are permitted)

6. Known sensitivity to gadolinium-DTPA

7. Contraindications to MRI such as non-MRI-compatible implanted devices

8. Large subjects not fitting comfortably into the MRI scanner

9. Difficulty laying supine and still for up to 4 hours in the MRI unit or claustrophobia

10. Untreated, uncontrolled Sleep apnea

11. Positive pregnancy test (for pre-menopausal women)

12. Known life-threatening systemic disease

13. More than 3 metastatic tumors

14. History of abnormal bleeding and coagulopathy

15. Use of Avastin in the preceding two weeks or planned use in the forthcoming two weeks and VEGF inhibitors within + 30 days of treatment

16. Patients with a history of uncontrolled seizures or who are not on anti seizure medication (e.g., Phenytoin 100 mg PO t.i.d. or Keppra 500 mg po bid) before the procedure
Brigham and Women's Hospital
Boston, Massachusetts, United States
Status: Recruiting
Contact: Danielle Chamberlain - 617-525-8596 -
Swedish Medical Center
Seattle, Washington, United States
Status: Recruiting
Contact: Colleen Ottinger - 206-320-3070 -
Start Date
August 2012
Completion Date
December 2015
Record processing date processed this data on July 28, 2015 page